Treatment of Nonalcoholic Steatohepatitis: A Review

Nonalcoholic steatohepatitis is a liver disease caused by metabolic dysfunction that has become one of the leading causes of cirrhosis and liver transplantation in the United States. The two most common risk factors for nonalcoholic steatohepatitis are obesity and insulin resistance, with patients frequently exhibiting metabolic syndrome symptoms. Patients who can modify these risk factors and are identified early in the course of their disease can experience histological improvement, including fibrosis arrest or improvement. Nonalcoholic steatohepatitis is linked to coronary artery, carotid artery, and peripheral vascular disease, with coronary artery disease being the most common cause of death. Despite the completion of several clinical trials evaluating a wide range of drugs aimed atOther than risk factor management, there is currently no approved treatment for nonalcoholic steatohepatitis development and progression. However, several promising clinical trials are currently underway, and the future appears bright. This article will discuss the most recent and significant medical advances in the treatment of nonalcoholic steatohepatitis.

Author (S) Details

Sandeep Mukherjee
Department of Medicine, Creighton University Medical Center, Division of Gastroenterology, Omaha, NE 68124, United States.

View Book :- https://stm.bookpi.org/TIPR-V7/article/view/1841

Leave a Reply

Your email address will not be published.

Previous post Determining the Intravenous Medication Administration Errors and Trying to Find Solutions
Next post Indian Black-Berry (Syzygium cumini) Seed Flour in Diabetic Study